Analytical Data
-
基因名
OCIAD2
- Application
-
别名
OCIAD2;OCIA domain-containing Protein 2
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q56VL3
-
表达区间
1-154aa
-
氨基酸序列
MGSSHHHHHHSSGLVPRGSHMGSMASASARGNQDKDAHFPPPSKQSLLFC PKSKLHIHRAEISKIMRECQEESFWKRALPFSLVSMLVTQGLVYQGYLAA NSRFGSLPKVALAGLLGFGLGKVSYIGVCQSKFHFFEDQLRGAGFGPQHN RHCLLTCEECKIKHGLSEKGDSQPSAS
-
分子量
19 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
OCIAD2, or Ovarian Cancer ImmunoassociaTed Antigen 2, is a cancer-associated antigen initially identified in ovarian cancer research. Its role in tumor immunology has drawn interest due to its potential as a biomarker for early detection of ovarian cancer and its involvement in immune responses against tumors. The study of OCIAD2, especially its recombinant form, aims to elucidate its structure-function relationships and enhance our understanding of cancer immunology. Given that ovarian cancer often presents at advanced stages, identifying specific biomarkers like OCIAD2 could facilitate earlier diagnosis and targeted therapies. Recombinant OCIAD2 proteins are being designed for use in immunological assays and vaccine development, providing insights into T-cell responses and antibody production against tumor antigens. As researchers investigate the antigen's immunogenic properties, the goal is to develop novel therapeutic strategies that leverage the immune system to better target and eliminate ovarian cancer cells. This approach is part of a broader trend in oncology, focusing on personalized medicine and immunotherapy to improve patient outcomes.
